Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001036154 | SCV001199505 | likely benign | Neurofibromatosis, type 1 | 2025-01-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004559841 | SCV005048231 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2021-10-05 | criteria provided, single submitter | clinical testing | The c.5473C>T (p.R1825W) alteration is located in exon 37 (coding exon 37) of the NF1 gene. This alteration results from a C to T substitution at nucleotide position 5473, causing the arginine (R) at amino acid position 1825 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004553567 | SCV004797640 | uncertain significance | NF1-related disorder | 2024-01-31 | no assertion criteria provided | clinical testing | The NF1 c.5536C>T variant is predicted to result in the amino acid substitution p.Arg1846Trp. This variant has been reported in an individual with neurofibromatosis type 1; however, it was also present in unaffected family members and therefore was not considered to be contributing to disease (referred to as p.Arg1825Trp in Ars et al. 2003. PubMed ID: 12807981). This variant has also been reported in an individual with breast cancer (Supplemental Data 1, Momozawa et al. 2018. PubMed ID: 30287823). This variant is reported in 0.0054% of alleles in individuals of East Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |